The major challenge facing Pfs25-based TBV development is to find a formulation with great safety profile and capable of inducing sustained high antibody responses. Previously the LMIV has demonstrated that conjugating Pfs25 with carrier protein ExoProtein A (EPA) of Psuedomonas aeruginosa greatly enhance the immunogenicity of the recombinant Pfs25 produced in Pichia pastoris. A process was developed to conjugate Pfs25 with rEPA, and cGMP-grade Pfs25-EPA conjugate was manufactured and formulated with Alhydrogel. A Phase 1 trial was conducted in US. After demonstrating that vaccine was safe, immunogenic, and could induce transmission reducing activity, LMIV began a Phase 1 trial in Mali, to evaluate the vaccine safety, immunogenicity, and transmission blocking activity in target population.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Zip Code
Eastman, Richard T; Pattaradilokrat, Sittiporn; Raj, Dipak K et al. (2013) A class of tricyclic compounds blocking malaria parasite oocyst development and transmission. Antimicrob Agents Chemother 57:425-35
Da, Dari F; Dixit, Saurabh; Sattabonkot, Jetsumon et al. (2013) Anti-Pfs25 human plasma reduces transmission of Plasmodium falciparum isolates that have diverse genetic backgrounds. Infect Immun 81:1984-9
Shimp Jr, Richard L; Rowe, Christopher; Reiter, Karine et al. (2013) Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle. Vaccine 31:2954-62
Zhu, Daming; Qian, Feng; Wu, Yimin et al. (2013) Determination of protein concentration for protein-protein conjugates using ultraviolet absorption. J Immunol Methods 387:317-21